Identification

Name
Adapalene
Accession Number
DB00210  (APRD00780)
Type
Small Molecule
Groups
Approved
Description

Adapalene is a topical retinoid primarily used in the treatment of acne and is also used (off-label) to treat keratosis pilaris as well as other skin conditions. It is currently marketed by Galderma under the trade names Differin in some countries, and Adaferin in India.

Structure
Thumb
Synonyms
  • 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid
  • Adaferin
  • Adapaleno
  • Adapalenum
  • Differine
External IDs
CD 271 / CD-271
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdapaleneGel3 mg/gTopicalOwen Laboratories2009-09-15Not applicableUs
AdapaleneLotion.1 g/100mLTopicalOwen Laboratories2010-03-31Not applicableUs
AdapaleneCream.1 g/100gTopicalPerrigo New York Inc.2010-10-26Not applicableUs
AdapaleneGel3 mg/gTopicalPrasco, Laboratories2014-01-01Not applicableUs
AdapaleneGel1 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1996-05-31Not applicableUs
DifferinGel1 mg/gTopicalGalderma1996-05-31Not applicableUs
DifferinGel3 mg/gTopicalPhysicians Total Care, Inc.2008-10-24Not applicableUs
DifferinGel3 mg/gTopicalGalderma2009-09-15Not applicableUs
DifferinGel1 mg/gTopicalPhysicians Total Care, Inc.2004-07-07Not applicableUs
DifferinLotion.1 g/100mLTopicalGalderma2010-03-31Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdapaleneGel3 mg/gTopicalSandoz2014-04-28Not applicableUs
AdapaleneCream1 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2010-06-30Not applicableUs
AdapaleneCream1 mg/gTopicalPhysicians Total Caer, Inc.2010-10-01Not applicableUs
AdapaleneGel1 mg/gTopicalA S Medication Solutions2010-07-012017-06-20Us
AdapaleneGel45 g/gTopicalPru Gen Pharmaceuticals2016-03-04Not applicableUs
AdapaleneGel1 mg/gTopicalA S Medication Solutions2010-06-022017-06-20Us
AdapaleneGel3 mg/gTopicalActavis Pharma Company2014-10-27Not applicableUs
AdapaleneGel1 mg/gTopicalGlenmark Pharmaceuticals Inc.,Usa2010-07-01Not applicableUs
AdapaleneGel1 mg/gTopicalTeva2010-06-02Not applicableUs
AdapaleneGel3 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2016-06-23Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DifferinGel1 mg/gTopicalGalderma2016-07-08Not applicableUs
Proactiv MD Adapalene Acne TreatmentGel.1 g/100gTopicalThe Proactiv Company, Llc2017-03-27Not applicableUs
International/Other Brands
Adaferin
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Adapalene and Benzoyl PeroxideAdapalene (1 mg/g) + Benzoyl peroxide (25 mg/g)GelTopicalPrasco, Laboratories2017-08-03Not applicableUs
Adapalene and Benzoyl PeroxideAdapalene (1 mg/g) + Benzoyl peroxide (25 mg/g)GelTopicalActavis Pharma Company2017-07-27Not applicableUs
EpiduoAdapalene (1 mg/g) + Benzoyl peroxide (25 mg/g)GelTopicalGalderma2008-12-08Not applicableUs
EpiduoAdapalene (1 mg/g) + Benzoyl peroxide (25 mg/g)GelTopicalPhysicians Total Care, Inc.2009-02-24Not applicableUs
Epiduo ForteAdapalene (3 mg/g) + Benzoyl peroxide (25 mg/g)GelTopicalGalderma2015-07-01Not applicableUs
TactupumpAdapalene (0.1 %) + Benzoyl peroxide (2.5 %)GelTopicalGalderma2011-05-13Not applicableCanada
Tactupump ForteAdapalene (0.3 %) + Benzoyl peroxide (2.5 %)GelTopicalGalderma2016-01-04Not applicableCanada
Categories
UNII
1L4806J2QF
CAS number
106685-40-9
Weight
Average: 412.5201
Monoisotopic: 412.203844762
Chemical Formula
C28H28O3
InChI Key
LZCDAPDGXCYOEH-UHFFFAOYSA-N
InChI
InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)
IUPAC Name
6-[3-(adamantan-1-yl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
SMILES
COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2

Pharmacology

Indication

For the topical treatment of comedo, papular and pustular acne (acne vulgaris) of the face, chest or back.

Structured Indications
Pharmacodynamics

Adapalene is a chemically stable retinoid-like compound. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes all of which represent important features in the pathology of acne vulgaris.

Mechanism of action

Mechanistically, adapalene binds to specific retinoic acid nuclear receptors (gamma and beta) and retinoid X receptors but does not bind to the cytosolic receptor protein. Although the exact mode of action of adapalene is unknown, it is suggested that topical adapalene may normalize the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.

TargetActionsOrganism
ARetinoic acid receptor gamma
agonist
Human
ARetinoic acid receptor beta
agonist
Human
ARetinoic acid receptor RXR-gamma
agonist
Human
ARetinoic acid receptor RXR-beta
agonist
Human
URetinoic acid receptor alpha
agonist
Human
NRetinoic acid receptor RXR-alpha
other/unknown
Human
Absorption

Absorption of adapalene through human skin is low. Only trace amounts (<0.25 ng/mL) of parent substance have been found in the plasma of acne patients following chronic topical application of adapalene in controlled clinical trials

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Metabolized mainly by O-demethylation, hydroxylation and conjugation, and excretion is primarily by the biliary route.

Route of elimination

Excretion appears to be primarily by the biliary route.

Half life
Not Available
Clearance
Not Available
Toxicity

The acute oral toxicity of adapalene in mice and rats is greater than 10 mL/kg. Chronic ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of Vitamin A.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Adapalene is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Adapalene is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Adapalene is combined with 5-androstenedione.Experimental, Illicit
AbciximabAdapalene may increase the anticoagulant activities of Abciximab.Approved
AcebutololAdapalene may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Adapalene is combined with Aceclofenac.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Adapalene is combined with Acemetacin.Approved
AcenocoumarolAdapalene may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Adapalene is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinAdapalene may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AlclofenacThe risk or severity of adverse effects can be increased when Adapalene is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Adapalene is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Adapalene is combined with Alendronic acid.Approved
AliskirenAdapalene may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Alminoprofen.Experimental
AlprenololAdapalene may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Adapalene.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Adapalene is combined with Amcinonide.Approved
AmikacinAdapalene may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideAdapalene may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinAdapalene may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodAdapalene may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Adapalene is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Adapalene is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Adapalene is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Adapalene is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Adapalene is combined with Anisodamine.Investigational
annamycinAdapalene may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Adapalene is combined with Antipyrine.Approved
Antithrombin III humanAdapalene may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanAdapalene may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Adapalene is combined with Apocynin.Investigational
ApramycinAdapalene may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Adapalene is combined with Apremilast.Approved, Investigational
ArbekacinAdapalene may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinAdapalene may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanAdapalene may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololAdapalene may decrease the antihypertensive activities of Arotinolol.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Adapalene is combined with Atamestane.Investigational
AtenololAdapalene may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Adapalene is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Adapalene.Approved
BalsalazideAdapalene may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminAdapalene may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Adapalene is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololAdapalene may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinAdapalene may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Adapalene.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Adapalene is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Adapalene.Approved
BenorilateThe risk or severity of adverse effects can be increased when Adapalene is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Adapalene.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Betamethasone.Approved, Vet Approved
BetaxololAdapalene may decrease the antihypertensive activities of Betaxolol.Approved
BevantololAdapalene may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Adapalene is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Adapalene.Approved, Investigational
BisoprololAdapalene may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAdapalene may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololAdapalene may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Adapalene is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Adapalene is combined with Bucillamine.Investigational
BucindololAdapalene may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Adapalene is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Adapalene is combined with Bufexamac.Experimental
BufuralolAdapalene may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Bumadizone.Experimental
BumetanideAdapalene may decrease the diuretic activities of Bumetanide.Approved
BupranololAdapalene may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Adapalene.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Adapalene.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Adapalene.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Adapalene is combined with Carbaspirin calcium.Experimental
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Adapalene.Approved
CarprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololAdapalene may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolAdapalene may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Adapalene is combined with Castanospermine.Experimental
CeliprololAdapalene may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinAdapalene may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Adapalene is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Adapalene.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Adapalene.Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Chlortetracycline is combined with Adapalene.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Adapalene.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Adapalene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Adapalene is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Adapalene is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Adapalene.Approved
CinoxacinAdapalene may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
Citric AcidAdapalene may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Adapalene is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Adapalene is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Adapalene is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Adapalene is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Adapalene is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Adapalene.Vet Approved
CloranololAdapalene may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Adapalene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Adapalene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe therapeutic efficacy of Conjugated estrogens can be decreased when used in combination with Adapalene.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Adapalene is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Adapalene is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Adapalene is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Adapalene is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Adapalene.Experimental
CyclosporineAdapalene may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Adapalene is combined with D-Limonene.Investigational
Dabigatran etexilateAdapalene may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinAdapalene may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAdapalene may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanAdapalene may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinAdapalene may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Adapalene is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Adapalene.Experimental
DemeclocyclineThe risk or severity of adverse effects can be increased when Demeclocycline is combined with Adapalene.Approved
DesirudinAdapalene may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Adapalene is combined with Desmopressin.Approved
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Adapalene.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Adapalene is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Adapalene is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Adapalene is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Adapalene.Approved
DextranAdapalene may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Adapalene may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Adapalene may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Adapalene may increase the anticoagulant activities of Dextran 75.Approved
DibekacinAdapalene may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Adapalene.Approved, Vet Approved
DicoumarolAdapalene may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Adapalene.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Adapalene.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Adapalene.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Adapalene is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Adapalene is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Adapalene is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Adapalene is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Adapalene.Approved
DihydrostreptomycinAdapalene may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Adapalene.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Adapalene.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Adapalene.Approved
DoxorubicinAdapalene may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Adapalene.Approved, Investigational, Vet Approved
DrospirenoneAdapalene may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Adapalene is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Adapalene is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Adapalene is combined with E-6201.Investigational
Edetic AcidAdapalene may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanAdapalene may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Adapalene.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Adapalene.Approved
EnoxacinAdapalene may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinAdapalene may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Adapalene.Experimental
EpanololAdapalene may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Adapalene is combined with Epirizole.Approved
EpirubicinAdapalene may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneAdapalene may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Adapalene.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Adapalene.Approved
EquileninThe risk or severity of adverse effects can be increased when Adapalene is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Adapalene is combined with Equilin.Approved
EsmololAdapalene may decrease the antihypertensive activities of Esmolol.Approved
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Adapalene.Approved, Investigational, Vet Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Adapalene.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Adapalene.Approved
EstroneThe risk or severity of adverse effects can be increased when Adapalene is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Adapalene is combined with Estrone sulfate.Approved
Etacrynic acidAdapalene may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Adapalene.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Adapalene is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Adapalene.Approved
Ethyl biscoumacetateAdapalene may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Adapalene.Approved
Etidronic acidThe risk or severity of adverse effects can be increased when Adapalene is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Adapalene is combined with Etofenamate.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Adapalene.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Adapalene is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Adapalene is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Adapalene is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Adapalene is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Adapalene.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Adapalene is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Feprazone.Experimental
Ferulic acidAdapalene may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Adapalene.Approved
FleroxacinAdapalene may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Adapalene.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Adapalene is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fludrocortisone.Approved
FluindioneAdapalene may increase the anticoagulant activities of Fluindione.Investigational
FlumequineAdapalene may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Adapalene is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Adapalene.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Adapalene is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Flurbiprofen.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Adapalene.Approved, Nutraceutical, Vet Approved
FondaparinuxAdapalene may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumAdapalene may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Adapalene.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Adapalene is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Adapalene.Approved
FramycetinAdapalene may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideAdapalene may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateAdapalene may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinAdapalene may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAdapalene may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Adapalene.Approved, Withdrawn
GemifloxacinAdapalene may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAdapalene may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAdapalene may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAdapalene may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Adapalene.Approved
GPX-150Adapalene may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinAdapalene may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Adapalene is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Adapalene is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Adapalene is combined with HE3286.Investigational
HeparinAdapalene may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Adapalene.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Adapalene is combined with Higenamine.Investigational
HydralazineAdapalene may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Adapalene.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Adapalene.Approved
Hygromycin BAdapalene may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Adapalene is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Adapalene is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Adapalene is combined with Icatibant.Approved
IdarubicinAdapalene may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxAdapalene may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Adapalene.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Adapalene.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Adapalene is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Adapalene.Approved
IndenololAdapalene may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Adapalene is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Adapalene is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Indoprofen.Withdrawn
INNO-206Adapalene may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Adapalene.Approved, Investigational
IsepamicinAdapalene may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Adapalene is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Adapalene is combined with Istaroxime.Investigational
KanamycinAdapalene may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Adapalene.Approved
LabetalolAdapalene may decrease the antihypertensive activities of Labetalol.Approved
LandiololAdapalene may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Adapalene.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Adapalene.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Adapalene is combined with Leflunomide.Approved, Investigational
LepirudinAdapalene may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanAdapalene may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololAdapalene may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinAdapalene may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Adapalene.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Adapalene.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Adapalene.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Adapalene is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Adapalene.Approved
LonazolacThe risk or severity of adverse effects can be increased when Adapalene is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Adapalene is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Adapalene.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Adapalene.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Adapalene.Vet Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Adapalene.Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Adapalene is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Adapalene.Approved
ME-609The risk or severity of adverse effects can be increased when Adapalene is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Adapalene is combined with Meclofenamic acid.Approved, Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Adapalene.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Adapalene is combined with Mefenamic acid.Approved
MelagatranAdapalene may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Adapalene is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Adapalene is combined with Meloxicam.Approved, Vet Approved
MepindololAdapalene may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineAdapalene may increase the nephrotoxic activities of Mesalazine.Approved
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Adapalene.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Adapalene is combined with Metamizole.Withdrawn
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Adapalene.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Adapalene.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Adapalene.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Adapalene is combined with Methylprednisolone.Approved, Vet Approved
MetipranololAdapalene may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Adapalene.Approved
MetoprololAdapalene may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideAdapalene may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinAdapalene may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MinocyclineThe risk or severity of adverse effects can be increased when Minocycline is combined with Adapalene.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Adapalene.Approved
MizoribineThe risk or severity of adverse effects can be increased when Adapalene is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Adapalene.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Adapalene.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Adapalene is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Adapalene is combined with Mycophenolic acid.Approved
NadololAdapalene may decrease the antihypertensive activities of Nadolol.Approved
NadroparinAdapalene may increase the anticoagulant activities of Nadroparin.Approved
NafamostatAdapalene may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Adapalene is combined with Naftifine.Approved
Nalidixic AcidAdapalene may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Adapalene is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Adapalene is combined with NCX 1022.Investigational
NeamineAdapalene may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinAdapalene may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinAdapalene may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Adapalene is combined with Nepafenac.Approved
NetilmicinAdapalene may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Adapalene is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Adapalene is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Adapalene is combined with Nitroaspirin.Investigational
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Adapalene.Approved
NorfloxacinAdapalene may increase the neuroexcitatory activities of Norfloxacin.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Adapalene.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Adapalene.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Adapalene is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Adapalene.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Adapalene is combined with Olopatadine.Approved
OlsalazineAdapalene may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Adapalene is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Adapalene.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Adapalene is combined with Orgotein.Vet Approved
OtamixabanAdapalene may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Adapalene is combined with Oxaprozin.Approved
Oxolinic acidAdapalene may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololAdapalene may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Adapalene is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Paramethasone.Approved
ParomomycinAdapalene may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Adapalene is combined with Parthenolide.Investigational
PazufloxacinAdapalene may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAdapalene may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololAdapalene may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateAdapalene may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Adapalene.Approved
PhenindioneAdapalene may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonAdapalene may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Adapalene is combined with Pimecrolimus.Approved, Investigational
PindololAdapalene may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidAdapalene may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinAdapalene may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideAdapalene may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pirfenidone.Investigational
Piromidic acidAdapalene may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Adapalene is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Pirprofen.Experimental
PlazomicinAdapalene may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinAdapalene may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Adapalene.Approved
PractololAdapalene may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Adapalene.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Pranoprofen.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Adapalene is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Adapalene is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Adapalene is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Adapalene is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Adapalene can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Adapalene is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Adapalene is combined with Propacetamol.Approved
PropranololAdapalene may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Adapalene.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Adapalene.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Adapalene.Vet Approved
Protein CAdapalene may increase the anticoagulant activities of Protein C.Approved
Protein S humanAdapalene may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAdapalene may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinAdapalene may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Adapalene is combined with PTC299.Investigational
PuromycinAdapalene may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Adapalene.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Adapalene.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Adapalene.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Adapalene.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Adapalene is combined with Resveratrol.Experimental, Investigational
ReviparinAdapalene may increase the anticoagulant activities of Reviparin.Approved
RibostamycinAdapalene may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Adapalene is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Adapalene is combined with Risedronate.Approved, Investigational
RivaroxabanAdapalene may increase the anticoagulant activities of Rivaroxaban.Approved
RosoxacinAdapalene may increase the neuroexcitatory activities of Rosoxacin.Approved
RufloxacinAdapalene may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinAdapalene may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Adapalene.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Adapalene is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Adapalene is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Adapalene is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Adapalene.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Adapalene.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Adapalene is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Adapalene is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Adapalene is combined with Serrapeptase.Investigational
SisomicinAdapalene may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinAdapalene may increase the neuroexcitatory activities of Sitafloxacin.Experimental
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Adapalene.Approved
SotalolAdapalene may decrease the antihypertensive activities of Sotalol.Approved
SP1049CAdapalene may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinAdapalene may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinAdapalene may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Adapalene.Approved
SpironolactoneAdapalene may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Adapalene is combined with SRT501.Investigational
StreptomycinAdapalene may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinAdapalene may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Adapalene is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Adapalene is combined with Sulindac.Approved
SulodexideAdapalene may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Adapalene.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Adapalene is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Adapalene.Approved
TacrolimusAdapalene may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Adapalene.Approved
TalinololAdapalene may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Adapalene.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Adapalene is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Adapalene.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Adapalene is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Adapalene is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Adapalene.Approved, Investigational
TemafloxacinAdapalene may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Adapalene.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Adapalene is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Adapalene is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Adapalene is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Adapalene is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Adapalene is combined with Teriflunomide.Approved
TertatololAdapalene may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Adapalene is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Adapalene is combined with Tiludronic acid.Approved, Vet Approved
TimololAdapalene may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Adapalene is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Adapalene is combined with Tixocortol.Approved
TobramycinAdapalene may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Adapalene is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Adapalene is combined with Tolmetin.Approved
TorasemideAdapalene may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Adapalene.Approved
TranilastThe risk or severity of adverse effects can be increased when Adapalene is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Adapalene.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Adapalene.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Adapalene is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAdapalene may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Adapalene is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Adapalene.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Adapalene is combined with Triptolide.Investigational
TrovafloxacinAdapalene may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TroxerutinAdapalene may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Adapalene.Approved
ValrubicinAdapalene may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Adapalene.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Adapalene.Approved
Vitamin AThe risk or severity of adverse effects can be increased when Vitamin A is combined with Adapalene.Approved, Nutraceutical, Vet Approved
WarfarinAdapalene may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAdapalene may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Adapalene is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Adapalene is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Adapalene.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Adapalene is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Adapalene is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinAdapalene may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinAdapalene may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Graziano Castaldi, Pietro Allegrini, Gabriele Razzetti, Mauro Ercoli, "Process for the preparation of adapalene." U.S. Patent US20060229465, issued October 12, 2006.

US20060229465
General References
  1. Rolewski SL: Clinical review: topical retinoids. Dermatol Nurs. 2003 Oct;15(5):447-50, 459-65. [PubMed:14619325]
External Links
Human Metabolome Database
HMDB14355
KEGG Drug
D01112
PubChem Compound
60164
PubChem Substance
46505019
ChemSpider
54244
BindingDB
50048280
ChEBI
31174
ChEMBL
CHEMBL1265
Therapeutic Targets Database
DAP000115
PharmGKB
PA448047
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Adapalene
ATC Codes
D10AD03 — AdapaleneD10AD53 — Adapalene, combinations
AHFS Codes
  • 84:92.00
PDB Entries
Not Available
FDA label
Download (25.9 KB)
MSDS
Download (57.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAcne Vulgaris1
1CompletedNot AvailableCutaneous Inflammation1
1CompletedTreatmentAcne Vulgaris3
1CompletedTreatmentSkin Manifestations2
1WithdrawnNot AvailableAcne Vulgaris1
2CompletedTreatmentAcne Scars1
2Unknown StatusTreatmentSenile Purpura1
3CompletedTreatmentAcne3
3CompletedTreatmentAcne Vulgaris3
3CompletedTreatmentPhotodamage / Solar Elastosis1
3CompletedTreatmentSolar Elastosis1
3Not Yet RecruitingTreatmentAcne Vulgaris1
3WithdrawnTreatmentAcne Vulgaris1
4Active Not RecruitingPreventionAcne Vulgaris / Atrophic Acne Scars1
4Active Not RecruitingTreatmentAcne Vulgaris1
4CompletedNot AvailableP Acnes Colonization1
4CompletedSupportive CareAcne1
4CompletedTreatmentAcne1
4CompletedTreatmentAcne Vulgaris18
4TerminatedTreatmentAcne Vulgaris1
4Unknown StatusTreatmentAcne Vulgaris1
Not AvailableCompletedNot AvailableAcne1
Not AvailableCompletedNot AvailableAcne Vulgaris1
Not AvailableCompletedTreatmentAcne Vulgaris2

Pharmacoeconomics

Manufacturers
  • Nycomed us inc
  • Galderma laboratories lp
  • Glenmark generics inc usa
  • Pliva hrvatska doo
  • Galderma research and development inc
  • Galderma Laboratories
Packagers
Dosage forms
FormRouteStrength
CreamTopical.1 g/100g
CreamTopical1 mg/g
GelTopical45 g/g
SwabTopical1 mg/mL
SolutionTopical1 mg/mL
CreamTopical0.1 %
GelTopical1 mg/g
GelTopical3 mg/g
LotionTopical.1 g/100mL
LotionTopical0.1 %
LotionTopical1 mg/g
GelTopical0.1 %
LiquidTopical0.1 %
GelTopical0.3 %
GelTopical
GelTopical.1 g/100g
Prices
Unit descriptionCostUnit
Differin 0.1% Cream 45 gm Tube227.13USD tube
Differin 0.1% Gel 45 gm Tube227.13USD tube
Differin 0.3% Gel 45 gm Tube219.65USD tube
Differin 0.1% cream4.85USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4717720No1993-05-312010-05-31Us
US8909305No2002-12-232022-12-23Us
US7579377No2005-02-232025-02-23Us
US7834060No2003-03-122023-03-12Us
US7868044No2003-03-122023-03-12Us
US8703820No2003-03-122023-03-12Us
US7838558No2003-03-122023-03-12Us
US7737181No2004-08-292024-08-29Us
US7964202No2004-09-012024-09-01Us
US8071644No2007-07-182027-07-18Us
US8080537No2007-07-182027-07-18Us
US8105618No2002-12-232022-12-23Us
US8129362No2007-07-182027-07-18Us
US8445543No2007-07-122027-07-12Us
US8809305No2002-12-232022-12-23Us
US8936800No2002-12-232022-12-23Us
US8241649No2002-12-232022-12-23Us
US7820186No2005-11-232025-11-23Us
US7998467No2008-05-312028-05-31Us
US8435502No2006-09-152026-09-15Us
US8709392No2006-09-152026-09-15Us
US8785420No2002-12-232022-12-23Us
US8729127No2003-03-122023-03-12Us
US9381179No2003-03-122023-03-12Us
US9387187No2003-03-122023-03-12Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityPractically InsolubleNot Available
logP8.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.01e-06 mg/mLALOGPS
logP6.06ALOGPS
logP6.46ChemAxon
logS-8ALOGPS
pKa (Strongest Acidic)3.99ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity122.07 m3·mol-1ChemAxon
Polarizability47.65 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7061
Caco-2 permeable+0.8439
P-glycoprotein substrateNon-substrate0.5408
P-glycoprotein inhibitor INon-inhibitor0.8074
P-glycoprotein inhibitor IIInhibitor0.5
Renal organic cation transporterNon-inhibitor0.8646
CYP450 2C9 substrateNon-substrate0.7171
CYP450 2D6 substrateNon-substrate0.8925
CYP450 3A4 substrateNon-substrate0.5116
CYP450 1A2 substrateNon-inhibitor0.7812
CYP450 2C9 inhibitorInhibitor0.7758
CYP450 2D6 inhibitorNon-inhibitor0.9466
CYP450 2C19 inhibitorNon-inhibitor0.653
CYP450 3A4 inhibitorNon-inhibitor0.8246
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8509
Ames testNon AMES toxic0.8575
CarcinogenicityNon-carcinogens0.8707
BiodegradationNot ready biodegradable0.9715
Rat acute toxicity2.6913 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9774
hERG inhibition (predictor II)Non-inhibitor0.8855
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as retinoids. These are oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Retinoids
Direct Parent
Retinoids
Alternative Parents
Phenylnaphthalenes / Naphthalenecarboxylic acids / Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
Adapalene / Phenylnaphthalene / 2-naphthalenecarboxylic acid / 2-naphthalenecarboxylic acid or derivatives / Naphthalene / Phenoxy compound / Anisole / Methoxybenzene / Phenol ether / Alkyl aryl ether
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
monocarboxylic acid, adamantanes (CHEBI:31174)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RARG
Uniprot ID
P13631
Uniprot Name
Retinoic acid receptor gamma
Molecular Weight
50341.405 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RARB
Uniprot ID
P10826
Uniprot Name
Retinoic acid receptor beta
Molecular Weight
50488.63 Da
References
  1. Shroot B, Michel S: Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997 Jun;36(6 Pt 2):S96-103. [PubMed:9204085]
  2. Shroot B, Michel S, Allec J, Chatelus A, Wagner N: A new concept of drug delivery for acne. Dermatology. 1998;196(1):165-70. [PubMed:9557255]
  3. Michel S, Jomard A, Demarchez M: Pharmacology of adapalene. Br J Dermatol. 1998 Oct;139 Suppl 52:3-7. [PubMed:9990413]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RXRG
Uniprot ID
P48443
Uniprot Name
Retinoic acid receptor RXR-gamma
Molecular Weight
50870.72 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Kim MJ, Ciletti N, Michel S, Reichert U, Rosenfield RL: The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J Invest Dermatol. 2000 Feb;114(2):349-53. [PubMed:10651997]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RXRB
Uniprot ID
P28702
Uniprot Name
Retinoic acid receptor RXR-beta
Molecular Weight
56921.38 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Kim MJ, Ciletti N, Michel S, Reichert U, Rosenfield RL: The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J Invest Dermatol. 2000 Feb;114(2):349-53. [PubMed:10651997]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RARA
Uniprot ID
P10276
Uniprot Name
Retinoic acid receptor alpha
Molecular Weight
50770.805 Da
References
  1. Shroot B, Michel S: Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997 Jun;36(6 Pt 2):S96-103. [PubMed:9204085]
  2. Griffiths CE, Ancian P, Humphries J, Poncet M, Rizova E, Michel S, Clucas A: Adapalene 0.1% gel and adapalene 0.1% cream stimulate retinoic acid receptor mediated gene transcription without significant irritative effects in the skin of healthy human volunteers. Br J Dermatol. 1998 Oct;139 Suppl 52:12-6. [PubMed:9990415]
  3. Michel S, Jomard A, Demarchez M: Pharmacology of adapalene. Br J Dermatol. 1998 Oct;139 Suppl 52:3-7. [PubMed:9990413]
  4. Shroot B, Michel S, Allec J, Chatelus A, Wagner N: A new concept of drug delivery for acne. Dermatology. 1998;196(1):165-70. [PubMed:9557255]
  5. Kim MJ, Ciletti N, Michel S, Reichert U, Rosenfield RL: The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J Invest Dermatol. 2000 Feb;114(2):349-53. [PubMed:10651997]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Other/unknown
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RXRA
Uniprot ID
P19793
Uniprot Name
Retinoic acid receptor RXR-alpha
Molecular Weight
50810.835 Da
References
  1. Bernard BA: Adapalene, a new chemical entity with retinoid activity. Skin Pharmacol. 1993;6 Suppl 1:61-9. [PubMed:8142113]
  2. Kim MJ, Ciletti N, Michel S, Reichert U, Rosenfield RL: The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J Invest Dermatol. 2000 Feb;114(2):349-53. [PubMed:10651997]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:33